Other active comparator
Basal bolus insulin
OTHER_ACTIVE_basal_bolus_insulin
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Exenatide extended release injection | MD 0.99 (-0.07 to 1.95) | 0.05 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 0.02 (-0.50 to 0.57) | 0.76 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 0.02 (-0.52 to 0.51) | 0.76 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 3.56 (1.14 to 5.87) | 0.28 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 3.53 (1.21 to 5.54) | 0.29 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | OR 1.05 (0.32 to 3.88) | 0.77 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | OR 1.04 (0.32 to 3.35) | 0.76 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 13.62 (0.86 to 258) | 0.07 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 10.21 (0.48 to 230) | 0.06 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.67 (0.74 to 32.58) | 0.30 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Dulaglutide flexible dose injection once weekly | HR 2.63 (0.21 to 42.30) | 0.30 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.37 (0.57 to 9.85) | 0.33 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 11.72 (1.91 to 84.80) | 0.06 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 11.46 (1.63 to 84.68) | 0.06 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.74 (0.35 to 1.56) | 0.62 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.71 (0.33 to 1.49) | 0.70 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.75 (0.12 to 15.64) | 0.49 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.55 (0.10 to 14.96) | 0.47 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.14 (0.04 to 0.44) | 0.95 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.14 (0.04 to 0.43) | 0.92 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.30 (0.00 to 9.24) | 0.78 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.70 (0.28 to 1.69) | 0.80 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.71 (0.27 to 1.83) | 0.75 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.77 (0.04 to 12.23) | 0.42 |
Trials
- NCT05767255Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue2022 · 65 randomized · 4 weeks
- IDEALINSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi2021 · 91 randomized · 24 weeks
- TRANSITION-T2DTransition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D) A Prospective Randomized Controlled Trial2021 · 60 randomized · 26 weeks
- BEYONDDurability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes: a Randomized Controlled Trial2019 · 305 randomized · 104.28 weeks
- NCT02846233Is the Stepping-down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?2016 · 22 randomized · 16 weeks
- NCT02887625Efficacy and Durability of Glucagon Like Peptide 1 Receptor Agonists (GLP-1 RA)/Thiazolidinedione Versus Basal Bolus Insulin Therapy in Poorly Controlled Type 2 Diabetic Patients (T2DM) Patients on Sulfonylurea Plus Metformin2015 · 251 randomized · 156.54 weeks
- NCT02420262A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus2015 · 506 randomized · 26 weeks